376 related articles for article (PubMed ID: 34941423)
1. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir, an Oral Antiviral Treatment for COVID-19.
Fischer W; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Loftis AJ; Alabanza P; Lipansky F; Painter WP
medRxiv; 2021 Jun; ():. PubMed ID: 34159342
[TBL] [Abstract][Full Text] [Related]
3. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
[TBL] [Abstract][Full Text] [Related]
4. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C;
N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868
[TBL] [Abstract][Full Text] [Related]
5. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
Johnson MG; Strizki JM; Jensen E; Cohen J; Katlama C; Fishchuk R; Ponce-de-León A; Fourie N; Cheng C-Y; McCoy D; Vesnesky M; Norice CT; Zhang Y; Williams-Diaz A; Brown ML; Carmelitano P; Grobler JA; Paschke A; De Anda C
Microbiol Spectr; 2024 Mar; 12(3):e0356323. PubMed ID: 38299867
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
Strizki JM; Grobler JA; Murgolo N; Fridman A; Johnson MG; Du J; Carmelitano P; Brown ML; Paschke A; De Anda C
Infect Dis Ther; 2023 Dec; 12(12):2725-2743. PubMed ID: 37995070
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.
Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y
Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723
[No Abstract] [Full Text] [Related]
11. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial.
Johnson MG; Puenpatom A; Moncada PA; Burgess L; Duke ER; Ohmagari N; Wolf T; Bassetti M; Bhagani S; Ghosn J; Zhang Y; Wan H; Williams-Diaz A; Brown ML; Paschke A; De Anda C
Ann Intern Med; 2022 Aug; 175(8):1126-1134. PubMed ID: 35667065
[TBL] [Abstract][Full Text] [Related]
12. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Johnson MG; Strizki JM; Brown ML; Wan H; Shamsuddin HH; Ramgopal M; Florescu DF; Delobel P; Khaertynova I; Flores JF; Fouche LF; Chang SC; Williams-Diaz A; Du J; Grobler JA; Paschke A; De Anda C
Infection; 2023 Oct; 51(5):1273-1284. PubMed ID: 36648627
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
15. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
16. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.
Standing JF; Buggiotti L; Guerra-Assuncao JA; Woodall M; Ellis S; Agyeman AA; Miller C; Okechukwu M; Kirkpatrick E; Jacobs AI; Williams CA; Roy S; Martin-Bernal LM; Williams R; Smith CM; Sanderson T; Ashford FB; Emmanuel B; Afzal ZM; Shields A; Richter AG; Dorward J; Gbinigie O; Van Hecke O; Lown M; Francis N; Jani B; Richards DB; Rahman NM; Yu LM; Thomas NPB; Hart ND; Evans P; Andersson M; Hayward G; Hood K; Nguyen-Van-Tam JS; Little P; Hobbs FDR; Khoo S; Butler C; Lowe DM; Breuer J;
Nat Commun; 2024 Feb; 15(1):1652. PubMed ID: 38396069
[TBL] [Abstract][Full Text] [Related]
18. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
[TBL] [Abstract][Full Text] [Related]
19. Molnupiravir in COVID-19: A systematic review of literature.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir: an antiviral drug against COVID-19.
Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
